Abstract
It is not my imagination—the incidence of bullous pemphigoid (BP) is increasing in my practice. This is a function of an aging population in concert with more drug-induced cases, notably with dipeptidyl peptidase IV inhibitors and anti–PD-1/PD-L1 agents. Treating BP is challenging—although corticosteroids are the bedrock of therapy, every effort is made to administer steroid-sparing medications. Options include dapsone, doxycycline, niacinamide, immunosuppressive agents (mycophenolate mofetil, azathioprine, others), and biologics (omalizumab, dupilumab, and rituximab [RTX]).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
